These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16212139)

  • 21. Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
    Ralston SH; Kou TD; Wick-Urban B; Steinbuch M; Masud T
    Calcif Tissue Int; 2010 Oct; 87(4):298-304. PubMed ID: 20803291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study.
    Malonne H; Coffiner M; Sonet B; Sereno A; Vanderbist F
    Clin Ther; 2004 Nov; 26(11):1774-82. PubMed ID: 15639689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
    Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
    Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
    Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
    Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.
    Cryer B; Miller P; Petruschke RA; Chen E; Geba GP; Papp AE
    Aliment Pharmacol Ther; 2005 Mar; 21(5):599-607. PubMed ID: 15740544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
    Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
    Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial.
    Blotman F; Maheu E; Wulwik A; Caspard H; Lopez A
    Rev Rhum Engl Ed; 1997 Dec; 64(12):825-34. PubMed ID: 9476272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.
    Bingham CO; Buckland-Wright JC; Garnero P; Cohen SB; Dougados M; Adami S; Clauw DJ; Spector TD; Pelletier JP; Raynauld JP; Strand V; Simon LS; Meyer JM; Cline GA; Beary JF
    Arthritis Rheum; 2006 Nov; 54(11):3494-507. PubMed ID: 17075851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
    Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
    J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
    Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
    J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
    Regula J; Butruk E; Dekkers CP; de Boer SY; Raps D; Simon L; Terjung A; Thomas KB; Lühmann R; Fischer R
    Am J Gastroenterol; 2006 Aug; 101(8):1747-55. PubMed ID: 16817839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial.
    Tugwell PS; Wells GA; Shainhouse JZ
    J Rheumatol; 2004 Oct; 31(10):2002-12. PubMed ID: 15468367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities.
    Baraf HS; Gold MS; Petruschke RA; Wieman MS
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):47-60. PubMed ID: 22264852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
    Lanza F; Sahba B; Schwartz H; Winograd S; Torosis J; Quan H; Reyes R; Musliner T; Daifotis A; Leung A
    Am J Gastroenterol; 2002 Jan; 97(1):58-64. PubMed ID: 11808969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
    Kivitz A; Eisen G; Zhao WW; Bevirt T; Recker DP
    J Fam Pract; 2002 Jun; 51(6):530-7. PubMed ID: 12100776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
    J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
    Bauer DC; Black D; Ensrud K; Thompson D; Hochberg M; Nevitt M; Musliner T; Freedholm D
    Arch Intern Med; 2000 Feb; 160(4):517-25. PubMed ID: 10695692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study.
    Eisman JA; Rizzoli R; Roman-Ivorra J; Lipschitz S; Verbruggen N; Gaines KA; Melton ME
    Curr Med Res Opin; 2004 May; 20(5):699-705. PubMed ID: 15140336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.